Matthew Jenkins, MD
Internal Medicine · Rock Hill, SCNPI 1467444133
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 691 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 51 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,949 and has fallen 95.8% since, to $125 in 2025. Among internal medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 691 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Sanofi-aventis U.S. LLC$1K
- AbbVie$872
- Lilly USA, LLC$683
- Pfizer$662
- AstraZeneca$644
- plus $6K from 45 others
What the payments were for
- Food & beverage$11,303100%
- Education$380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$361
- Omnia$144
- Inspire$139
- RYBELSUS$125
- TOUJEO$125
- SOLIQUA 100/33$120
- NEXLIZET$110
- NEXLETOL$110
- Senza Spinal Cord Stimulation System$109
How this compares
$11,342 in reported general payments places this provider in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 162 | $185,573 |
| FarxigaDapagliflozin Propanediol | 95 | $60,471 |
| OzempicSemaglutide | 44 | $45,877 |
| EliquisApixaban | 39 | $36,582 |
| JardianceEmpagliflozin | 31 | $34,877 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $29,617 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $26,384 |
| JanuviaSitagliptin Phosphate | 32 | $20,722 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $17,968 |
| RybelsusSemaglutide | 13 | $13,234 |
| MyrbetriqMirabegron | 16 | $10,216 |
| Rosuvastatin Calcium | 291 | $5,978 |
| Atorvastatin Calcium | 398 | $5,329 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $4,795 |
| Olmesartan Medoxomil | 129 | $3,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $683 | $185,573162 claims |
| AstraZenecaFarxiga | $644 | $60,47195 claims |
| Novo NordiskOzempic, Rybelsus | $1,710 | $59,11157 claims |
| PfizerEliquis | $662 | $36,58239 claims |
| Boehringer IngelheimJardiance | $267 | $34,87731 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,163 | $26,38419 claims |
| MerckJanuvia | $290 | $20,72232 claims |
| Astellas Pharma US IncMyrbetriq | $478 | $10,21616 claims |
| GSKArexvy | $86 | $3,53912 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $198 | $3,49615 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $3,322235 claims |
| AbbVieSynthroid | $872 | $2,88641 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Rock Hill
- Rajesh KedarRock Hill$14K
- Randolph VillamorRock Hill$13K
- John HoitinkRock Hill$12K
- Rhea HsuRock Hill$11K
- Jerry BackNorth Charleston$322K
- Jan BasileCharleston$278K
- Mark PurcellGreenville$165K
- John CleekCharleston$136K
- William BunnHilton Head Island$125K
- Zion LammGreenville$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.